Literature DB >> 15572627

HIV status of sexual partners is more important than antiretroviral treatment related perceptions for risk taking by HIV positive MSM in Montreal, Canada.

J Cox1, J Beauchemin, R Allard.   

Abstract

OBJECTIVE: To examine the role of antiretroviral treatment related perceptions relative to other clinical and psychosocial factors associated with sexual risk taking in HIV positive men who have sex with men (MSM).
METHODS: Participants were recruited from ambulatory HIV clinics in Montreal. Information on sociodemographic factors, health status, antiretroviral treatment related perceptions, and sexual behaviours was collected using a self administered questionnaire. At-risk sexual behaviour was defined as at least one occurrence of unprotected insertive or receptive anal intercourse in the past 6 months. Multivariate logistic regression was performed to evaluate the associations between at-risk sexual behaviour and covariates.
RESULTS: 346 subjects participated in the study. Overall, 34% of subjects were considered at risk; 43% of sexually active subjects (n=274). At-risk sexual behaviour was associated with two antiretroviral treatment related perceptions: (1) taking antiretroviral treatment reduces the risk of transmitting HIV (adjusted odds ratio (OR), 2.10; 95% confidence interval (CI), 1.16 to 3.80); and (2) there is less safer sex practised by MSM because of HIV treatment advances (OR, 1.82; CI, 1.14 to 2.90). Other factors, however, were more strongly associated with risk. These were: (1) safer sex fatigue (OR, 3.23; CI, 1.81 to 5.78); (2) use of "poppers" during sexual intercourse (OR, 6.28; CI, 2.43 to 16.21); and (3) reporting a greater proportion of HIV positive anal sex partners, compared with reporting no HIV positive anal sex partners: (a) <50% HIV positive (OR, 16.79; CI, 4.70 to 59.98); (b) > or =50% HIV positive (OR, 67.67; CI, 15.43 to 296.90).
CONCLUSION: Despite much emphasis on HIV treatment related beliefs as an explanation for sexual risk taking in MSM, this concern may play a relatively minor part in the negotiation of risk by HIV positive MSM. Serosorting, safer sex fatigue, and the use of poppers appear to be more important considerations in understanding the sexual risk behaviours of HIV positive MSM.

Entities:  

Mesh:

Year:  2004        PMID: 15572627      PMCID: PMC1744941          DOI: 10.1136/sti.2004.011288

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  23 in total

Review 1.  Towards an understanding of sexual risk behavior in people living with HIV: a review of social, psychological, and medical findings.

Authors:  Nicole Crepaz; Gary Marks
Journal:  AIDS       Date:  2002-01-25       Impact factor: 4.177

2.  Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco.

Authors:  Mitchell H Katz; Sandra K Schwarcz; Timothy A Kellogg; Jeffrey D Klausner; James W Dilley; Steven Gibson; William McFarland
Journal:  Am J Public Health       Date:  2002-03       Impact factor: 9.308

3.  Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection.

Authors:  Jean-Michel Tassie; Sophie Grabar; Rémi Lancar; Jacqueline Deloumeaux; Michèle Bentata; Dominique Costagliola
Journal:  J Acquir Immune Defic Syndr       Date:  2002-05-01       Impact factor: 3.731

4.  High-risk behaviors among men who have sex with men in 6 US cities: baseline data from the EXPLORE Study.

Authors:  Beryl A Koblin; Margaret A Chesney; Marla J Husnik; Sam Bozeman; Connie L Celum; Susan Buchbinder; Kenneth Mayer; David McKirnan; Franklyn N Judson; Yijian Huang; Thomas J Coates
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

5.  The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals.

Authors:  R S Janssen; D R Holtgrave; R O Valdiserri; M Shepherd; H D Gayle; K M De Cock
Journal:  Am J Public Health       Date:  2001-07       Impact factor: 9.308

6.  Determinants of sexual risk-taking among young HIV-negative gay and bisexual men.

Authors:  S A Strathdee; R S Hogg; S L Martindale; P G Cornelisse; K J Craib; J S Montaner; M V O'Shaughnessy; M T Schechter
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-09-01

7.  Towards an understanding of risk behavior: an AIDS risk reduction model (ARRM).

Authors:  J A Catania; S M Kegeles; T J Coates
Journal:  Health Educ Q       Date:  1990

8.  Protease inhibitor combination therapy and decreased condom use among gay men.

Authors:  Ralph J DiClemente; Ellen Funkhouser; Gina Wingood; Hala Fawal; Scott D Holmberg; Sten H Vermund
Journal:  South Med J       Date:  2002-04       Impact factor: 0.954

9.  Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men.

Authors:  David E Ostrow; Kelly J Fox; Joan S Chmiel; Anthony Silvestre; Barbara R Visscher; Peter A Vanable; Lisa P Jacobson; Steffanie A Strathdee
Journal:  AIDS       Date:  2002-03-29       Impact factor: 4.177

10.  Delayed application of condoms is a risk factor for human immunodeficiency virus infection among homosexual and bisexual men.

Authors:  Liviana Calzavara; Ann N Burchell; Robert S Remis; Carol Major; Paul Corey; Ted Myers; Margaret Millson; Evelyn Wallace
Journal:  Am J Epidemiol       Date:  2003-02-01       Impact factor: 4.897

View more
  27 in total

1.  Behavioural risks for HIV infection among Quebec residents of Haitian origin.

Authors:  Alix Adrien; Joseph Cox; Pascale Leclerc; Jean-François Boivin; Chris Archibald; David Boulos; Joseph Jean-Gilles; Gabriel Joseph; Claude Tremblay
Journal:  J Immigr Minor Health       Date:  2010-12

2.  Positive, negative, unknown: assumptions of HIV status among HIV-positive men who have sex with men.

Authors:  Jeffrey T Parsons; Joseph Severino; Jose Nanin; Joseph C Punzalan; Kirk von Sternberg; Whitney Missildine; David Frost
Journal:  AIDS Educ Prev       Date:  2006-04

3.  Sexual risk behavior and drug use in two Chicago samples of men who have sex with men: 1997 vs. 2002.

Authors:  Michael Fendrich; Mary Ellen Mackesy-Amiti; Timothy P Johnson; Lance M Pollack
Journal:  J Urban Health       Date:  2010-05       Impact factor: 3.671

4.  Analysis of rectal Chlamydia trachomatis serovar distribution including L2 (lymphogranuloma venereum) at the Erasmus MC STI clinic, Rotterdam.

Authors:  R Waalboer; E M van der Snoek; W I van der Meijden; P G H Mulder; J M Ossewaarde
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

5.  HIV treatment optimism and unsafe anal intercourse among HIV-positive men who have sex with men: findings from the positive connections study.

Authors:  David J Brennan; Seth L Welles; Michael H Miner; Michael W Ross; B R Simon Rosser
Journal:  AIDS Educ Prev       Date:  2010-04

Review 6.  Serosorting and the evaluation of HIV testing and counseling for HIV prevention in generalized epidemics.

Authors:  Georges Reniers; Stéphane Helleringer
Journal:  AIDS Behav       Date:  2011-01

7.  Evidence for the long-term stability of HIV transmission-associated sexual behavior after HIV diagnosis.

Authors:  Julia C Dombrowski; Robert D Harrington; Matthew R Golden
Journal:  Sex Transm Dis       Date:  2013-01       Impact factor: 2.830

8.  HIV treatment optimism and its predictors among young adults in southern Malawi.

Authors:  Sara Yeatman; Kathryn Dovel; Amy Conroy; Hazel Namadingo
Journal:  AIDS Care       Date:  2012-12-11

9.  Serosorting is associated with a decreased risk of HIV seroconversion in the EXPLORE Study Cohort.

Authors:  Susan S Philip; Xuesong Yu; Deborah Donnell; Eric Vittinghoff; Susan Buchbinder
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

10.  Sexual seroadaptation: lessons for prevention and sex research from a cohort of HIV-positive men who have sex with men.

Authors:  J Jeff McConnell; Larry Bragg; Stephen Shiboski; Robert M Grant
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.